Your session is about to expire
← Back to Search
Camu Camu Capsules for Human Immunodeficiency Virus Infection
Phase 1
Waitlist Available
Led By Jean-Pierre Routy, MD
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Able to communicate adequately in either French or English.
3.2 Inclusion Criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks and 20 wekks
Awards & highlights
Study Summary
This trial will investigate if a natural product can help people with HIV by reducing inflammation and risks of obesity, diabetes and cardiovascular diseases.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks and 20 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks and 20 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Reduction of the plasma marker of microbial translocation LPS, assessed using ELISA.
Secondary outcome measures
Association between baseline gut microbiota composition (16S rDNA sequencing), and markers of gut integrity (I-FABP, tissue staining) and inflammation (T-cell activation, inflammatory cytokines).
Changes in A. muciniphila levels in stools using qPCR
Changes in HIV reservoir size in biopsies using qPCR
+10 moreOther outcome measures
Biopsy
Exploratory: Difference in HIV reservoir size from Baseline (Visit 0) to 12 weeks post-CC treatment by TILDA, performed on blood samples
Trial Design
1Treatment groups
Experimental Treatment
Group I: Camu CamuExperimental Treatment1 Intervention
Assessments will be done at baseline, during and after 12 weeks of Camu Camu intake.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Camu Camu Capsules
2020
Completed Phase 1
~30
Find a Location
Who is running the clinical trial?
McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
437 Previous Clinical Trials
158,999 Total Patients Enrolled
Jean-Pierre Routy, MDPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre
3 Previous Clinical Trials
119 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
New York
What portion of applicants met pre-screening criteria?
Met criteria
Share this study with friends
Copy Link
Messenger